MMED Stock Summary and Trading Ideas (Minimed Group | NASDAQ:MMED)

Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.

Minimed Group trades on the NASDAQ stock market under the symbol MMED.

As of July 10, 2026, MMED stock price climbed to $15.29 with 773,235 million shares trading.

MMED has a beta of 0.41, meaning it tends to be less sensitive to market movements. MMED has a correlation of 0.01 to the broad based SPY ETF.

MMED has a market cap of $4.29 billion. This is considered a Mid Cap stock.

Last quarter Minimed Group reported $837 million in Revenue and -$.68 earnings per share. This beat revenue expectation by $10 million and missed earnings estimates by -$.46.

The top ETF exchange traded funds that MMED belongs to (by Net Assets): IWM, FPX, IWN, MGMT, SCHA.

MMED support price is $14.50 and resistance is $15.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MMED shares will trade within this expected range on the day.